Finding New Drugs Is Laborious. This AI Startup Is Skipping The Lab Work
AIPotential Sciences, a British AI startup, launched on November 5 with seed funding in the tens of millions of dollars from SovAI, the UK government's AI venture capital fund, and Twin Path Ventures. The company plans to generate large synthetic chemical datasets by simulating atomic and molecular interactions with physics, then use them to train AI models that predict drug candidates.
AIWhy it matters.
The article explains why physics-based simulation data is pitched as a route past the limits of the Protein Data Bank, and where skeptics say the bottleneck remains.
Source details
Wired · AI · Joel Khalili · wired.comPublished · added here